People

Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo  Dual inhibition of BAFF and APRIL validated as a transformative B-cell approach, highlighting telitecicept’s potential as a disease-modifying therapy for systemic lupus erythematosus BOSTON,...